This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version   RSS   Subscribe   Unsubscribe   Archive   Media Kit          June 02, 2015

Home  |   About ASHI  |   Education  |   Publications  |   Meetings  |   Careers  |   News  |   Lab Center


Proficiency Testing
Click here to place your 2015 Proficiency Testing order or to view your previous Performance and Summary reports.

Renew Your Membership Now!
It's not too late to renew your ASHI membership. If you haven't received your second dues renewal notice, please contact the ASHI central office at info@ashi-hla.org.

ASHI U
Access to educational information is free to ASHI members. CECs are awarded through an online testing process and are free to ASHI members.
 


ASSOCIATION NEWS


3 days left! Deadline is Friday, June 5! ASHI Technologists Survey
Have you taken ASHI's Technologist Survey yet?

The ASHI Technologist Affairs Committee is conducting a survey of all HLA technologists in North America. This survey is completely anonymous and consists of general questions from location and gender to more specific questions like salary information and compensation for on-call pay. Please take time to thoughtfully answer each question and feel free to add any comments or other information at the end of the survey. Our goal is for each North American HLA technologist to have the opportunity to take this survey so if someone in your lab did not receive the email link please forward the email to them. Once the survey results are tabulated, the summary will be made available on the ASHI website inside the member’s only section.

The ASHI Technologist Affairs Committee wants to thank you in advance for your participation in this important survey!!
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


2015 board election and proposed bylaws amendents ballot

Ballots will be mailed out to full-doctoral and non-doctoral ASHI members the first week in June.

IMPORTANT NOTICE

The following guidelines must be followed in order for these ballots to be valid.
  1. Do not write your name on this ballot.
  2. Print and sign your name on the inside flap of the pre-addressed return envelope. If the envelope is received without this information, the ballot will be invalid.
  3. Place your completed ballot in the pre-addressed return envelope, seal and mail.
  4. To be counted, your ballot must be postmarked by August 3, 2015. Ballots postmarked after that date will be invalid.
  5. Only the original ballot will be accepted for tabulation of votes. Ballots that have been copied or altered in any way will not be counted.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


MISSED AN ISSUE OF ASHI INSIGHTS?
Click here
to visit the ASHI Insights archive page.


Become an ASHI Corporate Supporter
By becoming an ASHI Corporate Supporter, your organization will benefit by contributing to ASHI's educational programs. Increase exposure to leading professionals, ASHI members, and non-members from all types of organizations and institutions, and the histocompatibility and immunogenetics community worldwide.
Contact Katherine Miranda at kmiranda@ahint.com to become a corporate sponsor today!

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


EDUCATION


Philadelphia Regional Education Workshop — June 18-20, 2015

There are still a few spaces left!
Deadline to Register — June 10


Register Now

Enter the Case Study Competition for a Chance to Win $500

Philadelphia Workshop submission deadline is Friday, June 5, 2015. Submit all case studies via e-mail to Lori Osowski at losowski@umm.edu.

Submission Details
  • First Come, First Serve entry, maximum of 5 case studies accepted per meeting
  • One $500 award per meeting
  • Open to only technologists and supervisors
  • Prepare a 10 minute Power Point presentation
  • Winners will be acknowledged in the ASHI Quarterly
There's so much to see and do in Philly! Make plans to stay and enjoy your time by visiting visitphilly.com.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


INDUSTRY NEWS


Clues to the HLA-RA connection from T-cell crossreactivity to vinculin and microorganisms
Nature
The HLA class II locus has long been implicated as a risk factor for rheumatoid arthritis (RA), particularly anti-citrullinated protein antibody (ACPA)-positive disease, but the molecular basis for the effects of HLA molecules has remained unclear.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Fibrosing mediastinitis complicating prior histoplasmosis is associated with human leukocyte antigen DQB1*04:02 — a case control study
BMC Infectious Diseases
Fibrosing mediastinitis is an idiosyncratic reaction to infection with Histoplasma capsulatum with a prevalence of 3:100,000 people infected. The rarity of post-histoplasmosis fibrosing mediastinitis (PHFM) in areas where H. capsulatum is endemic suggests that an abnormal immunological host response may be responsible for the development of fibrosis. Our group previously reported an association between subjects with PHFM and human leukocyte antigen (HLA)-A*02. We sought to confirm or extend those findings with application of high resolution HLA typing in a cohort of subjects with PHFM.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


HLA-G*01:04~UTR3 recipient correlates with lower survival and higher frequency of chronic rejection after lung transplantation
American Journal of Transplantation
Lung transplantation is a valid therapeutic option for selected patients with end-stage lung disease. Soluble HLA-G (sHLA-G) has been associated with increased graft survival and decreased rejection episodes in solid organ transplantation. HLA-G haplotypes named UTRs, defined by SNPs from both the 5'URR and 3'UTR, have been reported to reliably predict sHLA-G level. The aim of this retrospective study was to determine the impact of HLA-G alleles and UTR polymorphism from LTx recipients on anti-HLA allo-immunization risk, overall survival and chronic rejection.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



ASHI Insights
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Esther Cho, Content Editor, 469.420.2671  
Contribute news


Learn how to add us to your safe sender list so our emails get to your inbox.

This edition of ASHI Insights was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!
Recent issues
May 19, 2015
May 5, 2015
April 21, 2015





7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063